Dementia Subtypes in China
نویسندگان
چکیده
منابع مشابه
Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu.
BACKGROUND Prevalences of Alzheimer disease (AD) and vascular dementia (VaD) in China reportedly differ from those in Western countries. OBJECTIVE To estimate prevalence of AD and VaD in 4 regions of China. DESIGN Cross-sectional, population-based prevalence survey with a stratified, multistage cluster sampling design. SETTING Rural (n = 99) and urbanized (n = 71) communities of Beijing, ...
متن کاملComparison of Hippocampal Volume in Dementia Subtypes
Aims. To examine the relationship between different types of dementia and hippocampal volume. Methods. Hippocampal volume was measured using FL3D sequence magnetic resonance imaging in 26 Alzheimer's, vascular dementia, mixed dementia, and normal pressure hydrocephalus patients and 15 healthy controls and also hippocampal ratio, analyzed. Minimental scale was used to stratify patients on cognit...
متن کاملpolitical economy of china in central asia
this research is about the political economy of china in central asia. in this research the political & economic interactions affected on chinas political economy in central asia are examined. chinas goal of presence in central asia including political-security, economic and energy goals is described in one part. in another part, the trade relations between china and central asian countries ar...
15 صفحه اولProgression to dementia in clinical subtypes of mild cognitive impairment.
OBJECTIVE To examine the outcome among patients diagnosed with different types of mild cognitive impairment (MCI). PATIENTS A follow-up examination (average follow-up period: 3.49 +/- 2.2 years) was performed in 81 cognitively impaired, non-demented patients aged >55 years at baseline. RESULTS 8 of 32 patients with amnestic MCI (25%), 22 of 41 patients with multiple-domain MCI (54%), and 3 ...
متن کاملMemantine hydrochloride in the treatment of dementia subtypes.
Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD). We conducted a review of the literature to determine the changes to the central glutamatergic neurotransmitter system in dementia subtypes and the available clinical evidence regarding the use of memantine in the treatment of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Neurology
سال: 2005
ISSN: 0003-9942
DOI: 10.1001/archneur.62.3.447